Bazedoxifene

DRUG7 trials

Conditions

Arthritis, RheumatoidBreast Cancer Stage IVHealthyMetastatic Invasive Breast CancerOsteoporosisOsteoporosis, PostmenopausalPostmenopausal OsteoporosisUnresectable Locally Advanced Invasive Breast Cancer

Phase 1

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

TerminatedNCT01634789

PfizerHealthy

Start: 2012-08-31End: 2012-11-30Updated: 2013-01-18

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

CompletedNCT02448771

Dana-Farber Cancer InstituteBreast Cancer Stage IV, Metastatic Invasive Breast Cancer, Unresectable Locally Advanced Invasive Breast Cancer

Start: 2015-07-09End: 2021-03-03Updated: 2022-10-24

Phase 2

Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

CompletedNCT00238745

Wyeth is now a wholly owned subsidiary of PfizerPostmenopausal Osteoporosis

Start: 2003-08-31End: 2007-03-31Target: 375Updated: 2007-12-20

Phase 4

Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

CompletedNCT02090400

Instituto PalaciosOsteoporosis, Postmenopausal

Start: 2013-05-31End: 2015-07-31Updated: 2015-09-09

Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

CompletedNCT02602704

Hanyang UniversityArthritis, Rheumatoid

Start: 2015-12-29End: 2018-12-01Updated: 2020-08-12

Unknown Phase

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

CompletedNCT01416194

PfizerOsteoporosis, Postmenopausal

Start: 2011-07-25End: 2019-04-30Updated: 2024-04-22

Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

CompletedNCT01470326

PfizerOsteoporosis

Start: 2011-11-30End: 2016-06-30Updated: 2018-11-05

2025-02-011 citations

Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

Clinical Cancer Research2022-10-1027 citations

Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer (ABC).

Journal of Clinical Oncology2022-06-012 citations

Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.

2021-07-026 citations